Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Estimating the value of novel interventions for Parkinson's disease: An early decision-making model with application to dopamine cell replacement.

Hjelmgren, Jonas ; Ghatnekar, Ola ; Reimer, Jan ; Grabowski, Martin ; Lindvall, Olle LU ; Persson, Ulf and Hagell, Peter (2006) In Parkinsonism & Related Disorders 12(7). p.443-452
Abstract
A long-term cost-effectiveness model for early decision-making and estimation of outcomes of novel therapeutic procedures for Parkinson's disease (PD) was developed based on the Hoehn and Yahr (HY) stages of PD. Results provided support for model validity. Model application to a future dopamine cell replacement therapy indicated long-term cost offsets and gains in quality-adjusted life years (QALYs) in early onset PD (HY III-IV), as compared to standard drug therapy. The maximum price premium (i.e., profit or compensation for developmental costs) for the intervention to remain cost-effective was estimated to EURO12000-64000 according to cost-per-QALY thresholds of EURO38000-70000 and depending on whether all or only medical direct costs... (More)
A long-term cost-effectiveness model for early decision-making and estimation of outcomes of novel therapeutic procedures for Parkinson's disease (PD) was developed based on the Hoehn and Yahr (HY) stages of PD. Results provided support for model validity. Model application to a future dopamine cell replacement therapy indicated long-term cost offsets and gains in quality-adjusted life years (QALYs) in early onset PD (HY III-IV), as compared to standard drug therapy. The maximum price premium (i.e., profit or compensation for developmental costs) for the intervention to remain cost-effective was estimated to EURO12000-64000 according to cost-per-QALY thresholds of EURO38000-70000 and depending on whether all or only medical direct costs are considered. The study illustrates the value of early health economic modeling and the described model shows promise as a means to estimate outcomes and aid decision-making regarding novel interventions for PD. (c) 2006 Elsevier Ltd. All rights reserved. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
cell, therapy, cost-effectiveness, Parkinson's disease, outcomes, modeling
in
Parkinsonism & Related Disorders
volume
12
issue
7
pages
443 - 452
publisher
Elsevier
external identifiers
  • wos:000241605700007
  • scopus:33748764131
ISSN
1873-5126
DOI
10.1016/j.parkreldis.2006.04.006
language
English
LU publication?
yes
additional info
The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Section I-II (013230011), Division IV (013230800), Division of Gerontology and Caring Sciences (Closed 2012) (013220200), Restorative Neurology (0131000160), Neurology, Lund (013027000), Caring Sciences (Closed 2012) (016514020)
id
f26aa2f5-4379-4568-a9ad-b687457477ad (old id 158123)
alternative location
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16798054&dopt=Abstract
date added to LUP
2016-04-01 11:52:11
date last changed
2021-10-06 03:45:57
@article{f26aa2f5-4379-4568-a9ad-b687457477ad,
  abstract     = {A long-term cost-effectiveness model for early decision-making and estimation of outcomes of novel therapeutic procedures for Parkinson's disease (PD) was developed based on the Hoehn and Yahr (HY) stages of PD. Results provided support for model validity. Model application to a future dopamine cell replacement therapy indicated long-term cost offsets and gains in quality-adjusted life years (QALYs) in early onset PD (HY III-IV), as compared to standard drug therapy. The maximum price premium (i.e., profit or compensation for developmental costs) for the intervention to remain cost-effective was estimated to EURO12000-64000 according to cost-per-QALY thresholds of EURO38000-70000 and depending on whether all or only medical direct costs are considered. The study illustrates the value of early health economic modeling and the described model shows promise as a means to estimate outcomes and aid decision-making regarding novel interventions for PD. (c) 2006 Elsevier Ltd. All rights reserved.},
  author       = {Hjelmgren, Jonas and Ghatnekar, Ola and Reimer, Jan and Grabowski, Martin and Lindvall, Olle and Persson, Ulf and Hagell, Peter},
  issn         = {1873-5126},
  language     = {eng},
  number       = {7},
  pages        = {443--452},
  publisher    = {Elsevier},
  series       = {Parkinsonism & Related Disorders},
  title        = {Estimating the value of novel interventions for Parkinson's disease: An early decision-making model with application to dopamine cell replacement.},
  url          = {https://lup.lub.lu.se/search/ws/files/2679429/625490.pdf},
  doi          = {10.1016/j.parkreldis.2006.04.006},
  volume       = {12},
  year         = {2006},
}